The Effects of Cebranopadol on Ventilatory Drive, Central Nervous System, and Pain (PAINWeek 2024) - Jul 31, 2024 - Abstract #P-017; Location: Exhibit Hall; "Although all doses of cebranopadol administered in the study had a greater analgesic potency than either dose of oxycodone, the PK/PD results were able to establish a model to compare respiratory depression at equianalgesic doses. The extensive PK/PD analysis highlighted cebranopadol's advantages over oxycodone, showing approximately 25% less respiratory depression for equivalent analgesia, attributed to NOP activation. In addition, cebranopadol featured prolonged analgesic effects, with a gradual onset and offset, and a longer time to peak impact on respiratory and pain parameters compared to oxycodone.Special consideration was given to safety parameters related to respiratory function (e.g., apnea/decreased saturation), which were significantly more frequent after oxycodone 60mg than any other treatment, occurring approximately 2 to 3 times more often."
Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Pain • Psychiatry
|
|
Simone C. Jansen, MD, PhDc; Antonio Pardo, MD; Joseph C. Grieco, PhD; James Hackworth, PhD; Albert Dahan, MD, PhD
|